Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
F8 encodes coagulation factor VIII, which participates in the intrinsic pathway of blood coagulation\; factor VIII is a cofactor for factor IXa which, in the presence of Ca+2 and phospholipids, converts factor X to the activated form Xa. Additionally we are shipping Factor VIII Kits (55) and Factor VIII Proteins (32) and many more products for this protein.
Showing 10 out of 336 products:
Human Monoclonal Factor VIII Primary Antibody for ELISA - ABIN394620
Bailey, Xie, Do, Montpetit, Diaz, Mohan, Keavney, Yusuf, Gerstein, Engert, Anand: Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study. in Diabetes Care 2010
Show all 5 references for ABIN394620
Dog (Canine) Polyclonal Factor VIII Primary Antibody for IF (p), IHC (p) - ABIN668601
Yu, Zhang, Jiang, Wang, Zhang: Astragalosides promote angiogenesis via vascular endothelial growth factor and basic fibroblast growth factor in a rat model of myocardial infarction. in Molecular medicine reports 2015
Show all 3 references for ABIN668601
Human Polyclonal Factor VIII Primary Antibody for IF (cc), IF (p) - ABIN728000
Zhou, Zhu, Zou, Wang: Changes in number and biological function of endothelial progenitor cells in hypertension disorder complicating pregnancy. in Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban 2008
Show all 2 references for ABIN728000
Human Monoclonal Factor VIII Primary Antibody for ELISA, WB - ABIN969123
Shovlin, Sulaiman, Govani, Jackson, Begbie: Elevated factor VIII in hereditary haemorrhagic telangiectasia (HHT): association with venous thromboembolism. in Thrombosis and haemostasis 2007
Show all 2 references for ABIN969123
Human Monoclonal Factor VIII Primary Antibody for EIA, RIA - ABIN120341
Rotblat, OBrien, OBrien, Goodall, Tuddenham: Purification of human factor VIII:C and its characterization by Western blotting using monoclonal antibodies. in Biochemistry 1985
Show all 2 references for ABIN120341
Human Polyclonal Factor VIII Primary Antibody for IF (p), IHC (p) - ABIN872493
Tang, Liu, Dong, Li, Li, Hou, Zheng, Lin, Ren: Protective Effect of Kaempferol on LPS plus ATP-Induced Inflammatory Response in Cardiac Fibroblasts. in Inflammation 2014
Show all 2 references for ABIN872493
Human Polyclonal Factor VIII Primary Antibody for ICC, IF - ABIN449338
Zhu, Liu, Miao, Qu, Chi: Enhanced plasma factor VIII activity in mice via cysteine mutation using dual vectors. in Science China. Life sciences 2012
Show all 2 references for ABIN449338
Dog (Canine) Polyclonal Factor VIII Primary Antibody for IHC, ELISA - ABIN1582291
Shen, Li, Chung, Gillies: Retinal vascular changes after glial disruption in rats. in Journal of neuroscience research 2010
Human Monoclonal Factor VIII Primary Antibody for EIA, IHC (fro) - ABIN112268
Stel, van der Kwast, Veerman: Detection of factor VIII/coagulant antigen in human liver tissue. in Nature 1983
gene is flanked by factor VII (show TH Antibodies) and factor X genes; gene encodes a protein homologous to factor VII (show TH Antibodies), but lacks critical residues for factor VII (show TH Antibodies) activity; functions as an inhibitor of blood coagulation in biochemical assays using zebrafish or human plasmas
the results indicate that residues in the C1 and/or C2 domains of factor VIII are implicated in immunogenic factor VIII uptake, at least in vitro Conversely, in vivo, the binding to endogenous von Willebrand factor (show VWF Antibodies) masks the reducing effect of mutations in the C domains on factor VIII immunogenicity.
data demonstrate that infusion of platelets containing FVIII triggers neither primary nor memory anti-FVIII immune response in FVIII(null) mice
Both platelet-VWF (show VWF Antibodies) and plasma-VWF (show VWF Antibodies) are required for optimal platelet-derived FVIII gene therapy for hemophilia A in the presence of inhibitors.
These data support the investigation of FVIII orthologs as treatment modalities in both the congenital and acquired FVIII inhibitor settings.
Activatable bioengineered FIX molecules with FVIII-independent activity might be a promising tool for improving hemophilia A treatment, especially for patients with inhibitors.
This study demonstrated that FVIIIa interacts with Low-density lipoprotein receptor-related protein 1 (show LRP1 Antibodies) cluster III.
a fragment containing only approximately 20% of the VWF (show VWF Antibodies) sequence is sufficient to support FVIII stability in vivo
Endothelial cells from multiple, but not all, tissues contribute to the plasma FVIII pool in the mouse.
Endothelial cells are the predominant, and possibly exclusive, source of plasma FVIII.
Micro-computed tomography analysis of distal tibia metaphyses also revealed for the first time a major impact of the FVIII/thrombin (show F2 Antibodies)/PAR1 (show F2R Antibodies) axis on the dynamic bone structure, showing reduced bone.
Our finding that the C2-domain of FVIII can be replaced by that of FV without compromising FVIII activity may have translational implications.
Galectin-1 (show LGALS1 Antibodies) and Galectin-3 (show LGALS3 Antibodies) are novel-binding partners for human FVIII. Gal-1 (show LGALS1 Antibodies) binding can influence the procoagulant activity of FVIII.
although fVIII bound avidly to soluble forms of clusters II and IV from LRP1 (show LRP1 Antibodies), only soluble cluster IV competed with the binding of fVIII to full-length LRP1 (show LRP1 Antibodies), revealing that cluster IV represents the major fVIII binding site in LRP1 (show LRP1 Antibodies).
The FVIII B domain variants, p.D963N, p.S806T, p.G873D, p.H998Q and p.Q1225R may be considered as polymorphism or non-pathologic mutations in patients with Haemophilia A.
In this meta-analysis, we have assessed the association between the FXIII-A Val34Leu polymorphism and intracerebral hemorrhage risk. The results of a combined analysis showed no significant association between the FXIII-A Val34Leu polymorphism and ICH (show COL4a2 Antibodies) risk in the overall population. The results of this meta-analysis suggest that the FXIII-A Val34Leu polymorphism is not associated with ICH (show COL4a2 Antibodies) risk in a Caucasian population.
von Willebrand factor (show VWF Antibodies) binds to the surface of dendritic cells and modulates peptide presentation of factor VIII.
Desmopressin acetate increases F8 plasma concentration in patients with combined deficiency of factors V and VIII (show COX8A Antibodies).
37 (70%) of the 53 had discordant antigen-activity ratio, majority of those mutations produced FVIII with low FVIII-specific activity. However, 4 (7.5%) of the 53 mutations produced higher specific activity of FVIII. It is possible that these mutations either produce a secretory defect or an increased metabolic turnover to account for the low levels of FVIII with these mutations.
Platelet-targeted FVIII gene therapy has higher therapeutic efficacy compared to factor VIII replacement therapy may be due to accelerated thrombin (show F2 Antibodies) generation.
thrombin (show F2 Antibodies) stimulates transglutaminase activity in articular cartilage by directly cleaving factor XIII (show UGDH Antibodies) and by receptor-mediated up-regulation of factor XIII (show UGDH Antibodies) synthesis
cupredoxin-like A1 subdomains in fVIII contain inter-species differences that are a result of selective pressure on the dissociation rate constant
Factor VIIIc (show COX7A2 Antibodies) is responsible for tissue invasion during tumor progression.
This gene encodes coagulation factor VIII, which participates in the intrinsic pathway of blood coagulation\; factor VIII is a cofactor for factor IXa which, in the presence of Ca+2 and phospholipids, converts factor X to the activated form Xa. This gene produces two alternatively spliced transcripts. Transcript variant 1 encodes a large glycoprotein, isoform a, which circulates in plasma and associates with von Willebrand factor in a noncovalent complex. This protein undergoes multiple cleavage events. Transcript variant 2 encodes a putative small protein, isoform b, which consists primarily of the phospholipid binding domain of factor VIIIc. This binding domain is essential for coagulant activity. Defects in this gene results in hemophilia A, a common recessive X-linked coagulation disorder.
, procoagulant component
, antihemophilic factor
, coagulation factor VIII
, coagulation factor VIIIc
, factor VIII F8B
, coagulation factor VIII, procoagulant component (hemophilia A)
, factor VIII
, coagulation co-factor